Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA

blonca9
Oct 3, 2024
1 min read

CEO John Lepore, who was previously head of research at GSK, describes how the company is screening all proteins that are made by ribosomes, and then tests the functionality of novel ones to see if they can be harnessed as therapeutics or new drug targets.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight